<DOC>
	<DOCNO>NCT02218372</DOCNO>
	<brief_summary>The purpose study investigate clinical response fidaxomicin oral suspension tablet vancomycin oral liquid capsule pediatric subject Clostridium difficile-associated diarrhea ( CDAD ) . It also investigate recurrence/sustained clinical response safety fidaxomicin vancomycin , well acceptance fidaxomicin oral suspension formulation .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy Fidaxomicin ( Oral Suspension Tablets ) Vancomycin ( Oral Liquid Capsules ) Pediatric Subjects With Clostridium Difficile-associated Diarrhea ( CDAD )</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Subject diagnose CDAD accord local diagnostic criterion . As minimum must positive detection , within 72 hour prior randomization , either toxin A and/or toxin B stool positive detection toxigenic C. difficile stool : Subject Birth &lt; 2 year : watery diarrhea 24 hour prior screen . Subject ≥ 2 year &lt; 18 year : ≥ 3 unformed bowel movement 24 hour prior screen . Male female subject age birth &lt; 18 year : Note United States America subject include age ≥ 6 month &lt; 18 year . For subject &lt; 5 year : Negative rotavirus test . Female subject childbearing potential : must negative urine pregnancy test Screening , must abstain sexual activity duration study , must use two form birth control ( least one must barrier method ) start Screening throughout study period 28 day final study drug administration . Female subject must breastfeed Screening study period , 28 day final study drug administration . Female subject must donate ovum start Screening throughout study period , 28 day final study drug administration . Subject agree participate another interventional study study ( exception study describe exclusion criterion ) . Concurrent use metronidazole , oral vancomycin antibiotic treatment CDAD . If investigator feel clinical imperative begin treatment know laboratory result toxigenic C. difficile , four dos 24 hour treatment metronidazole , oral vancomycin effective treatment CDAD allow . Subject pseudomembranous colitis , fulminant colitis , toxic megacolon ileus . Subject history inflammatory bowel disease ( e.g. , ulcerative colitis Crohn 's disease etc. ) . Subject diarrhea cause agent C. difficile ( e.g . infection , infestation , drug etc. ) . Subject know hypersensitivity fidaxomicin , vancomycin excipients teicoplanin . Subject receive investigational therapy within 28 day , prior Screening , exception study primary treatment cancer without novel Investigational Medicinal Product ( IMP ) affect assessment diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Clostridium difficile-associated Diarrhea ( CDAD )</keyword>
	<keyword>vancomycin</keyword>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>fidaxomicin</keyword>
</DOC>